SEC Company Response from Arbutus Biopharma Corp (ABUS) (CIK 0001447028) (ABUS) — Jan 8, 2020
Arbutus Biopharma Corp (ABUS) (CIK 0001447028)
Date: Jan. 8, 2020 · CIK: 0001447028 · Accession: 0001447028-20-000004
AI Filing Summary & Sentiment
File numbers found in text: 333-235674
Letter
Document
Arbutus Biopharma Corporation
701 Veterans Circle
Warminster, Pennsylvania 18974
January 8, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Arbutus Biopharma Corporation
Registration Statement on Form S-3
Filed December 23, 2019
File No. 333-235674
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Arbutus Biopharma Corporation hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) to become effective on January 10, 2020, at 4:00 p.m. Eastern Standard Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Steve Abrams of Hogan Lovells US LLP at (267) 675-4671.
ARBUTUS BIOPHARMA CORPORATION
By: /s/ David C. Hastings
Name: David C. Hastings
Title:
Chief Financial Officer
Show Raw Text
CORRESP 1 filename1.htm Document Arbutus Biopharma Corporation 701 Veterans Circle Warminster, Pennsylvania 18974 January 8, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Arbutus Biopharma Corporation Registration Statement on Form S-3 Filed December 23, 2019 File No. 333-235674 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Arbutus Biopharma Corporation hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) to become effective on January 10, 2020, at 4:00 p.m. Eastern Standard Time, or as soon thereafter as is practicable. Once the Registration Statement has been declared effective, please orally confirm that event with Steve Abrams of Hogan Lovells US LLP at (267) 675-4671. ARBUTUS BIOPHARMA CORPORATION By: /s/ David C. Hastings Name: David C. Hastings Title: Chief Financial Officer